CO17

Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - CO17

CO17 Details
Status: Closed
Activation Date: 2003AUG28
Closing Date: 2005AUG26
Phase: III

Description: A Phase III Randomized Study of Cetuximab (Erbitux TM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR) - Positive Colorectal Carcinoma

Eligibility: Patients with pre-treated metastatic EGFR-positive colorectal carcinoma.

Objective: Primary To compare survival Secondary To compare the time to disease progression To compare the objective response rate To compare the quality of life in patients To conduct a comparative economic evaluation To evaluate the safety profile of cetuximab administered weekly

Participation: NCIC CTG and AGITG centres.

Lay Description: The purpose of the study is to compare the effects on colon cancer of a new drug, cetuximab, and best supportive care (BSC) compared to BSC alone.

Primary Publication Show

Other Publications Show

Year: 2008
Title: KRAS mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer ? results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care
Authors: Karapetis CS;Khambata-Ford S;Jonker DJ;O'Callaghan CJ;Tu D;Tebbutt NC;Simes RJ;Langer C;Moore MJ;Zalcberg JR;
Reference: World Congress on Gastrointestinal Cancer 2008 May 20; ( )
Link:

Year: 2008
Title: K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Authors: Karapetis CS;Khambata-Ford S;Jonker DJ;O'Callaghan CJ;Tu D;Tebbutt NC;Simes RJ;Chalchal H;Shapiro JD;Robitaille S;Price TJ;Shepherd L;Au H;Langer C;Moore MJ;Zalcberg JR;
Reference: New England Journal of Medicine 2008 Oct 23; 359 (17)
Link:

Year: 2009
Title: Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial
Authors: Au H;Karapetis CS;O'Callaghan CJ;Tu D;Moore MJ;Zalcberg JR;Kennecke H;Shapiro JD;Koski S;Pavlakis N;Charpentier D;Wyld D;Jefford M;Knight GJ;Magoski NM;Brundage MD;Jonker DJ;
Reference: Journal of Clinical Oncology 2009 Apr 10; 27 (11)
Link: http://jco.ascopubs.org/content/27/11/1822.abstract

Year: 2009
Title: High epiregulin gene expression plus K-ras wild-type status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer: Results from NCIC CTG CO.17 - A phase III trial of cetuximab versus best supportive care
Authors: Jonker DJ;Karapetis C;Harbison C;O'Callaghan CJ;Tu D;Simes RJ;Xu L;Moore MJ;Zalcberg JR;Khambata-Ford S;
Reference: Journal of Clinical Oncology 2009 May 29; 27 (15s Part 1, abstr 4016)
Link: http://meetinglibrary.asco.org/content/34969-65

Year: 2016
Title: Fc-y Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
Authors: Liu G;Tu D;Lewis M;Cheng D;Sullivan LA;Chen Z;Morgen E;Simes J;Price TJ;Tebbutt NC;Shapiro JD;Jeffery GM;Mellor JD;Mikeska T;Virk S;Shepherd LE;Jonker DJ;O'Callaghan CJ;Zalcberg JR;Karapetis CS;Dobrovic A;
Reference: Clinical Cancer Research 2016 May 15; 22 (10)
Link: http://clincancerres.aacrjournals.org/content/22/10/2435.abstract

Inventory
Hide Tissue Samples

Disease Site	Trial Code	Patients Accrued	Patients - Blocks	Patients - Slides	Patients - Blocks and/or Slides
GASTRO-INTESTINAL	CO17	1243	322	497	497

Hide TMA Samples

(Core size is 0.6 mm)

Disease Site	Trial Code	Patients Accrued	TMA Blocks	Patients on TMA Blocks
GASTRO-INTESTINAL	CO17	1243	6	216

Hide Fluid Samples

Disease Site	Trial Code	Patients Accrued	Patients - Whole Blood	Patients - Cellular Component of Blood	Patients - DNA extracted from Blood	Patients - RNA extracted from Blood	Patients - Plasma	Patients - Serum	Patients - Urine	Patients - Buccal
GASTRO-INTESTINAL	CO17	1243	0	0	0	0	0	0	0	0